What is Lixte Biotechnology Holdings, Inc.'s contact information?

Lixte Biotechnology Holdings, Inc.'s contact information: info@lixte.com, eforman@lixte.com, (631) 830-7092, +16318307092.

How many employees does Lixte Biotechnology Holdings, Inc. have?

Lixte Biotechnology Holdings, Inc. has 5 employees.

What industry does Lixte Biotechnology Holdings, Inc. belong to?

Lixte Biotechnology Holdings, Inc. is in the industry of: Pharmaceuticals, Biotechnology, Healthcare.

What are Lixte Biotechnology Holdings, Inc.'s official social media profiles?

Lixte Biotechnology Holdings, Inc. Linkedin Page Lixte Biotechnology Holdings, Inc. Twitter Page

What tech stack does Lixte Biotechnology Holdings, Inc. use?

Some of the popular technologies that Lixte Biotechnology Holdings, Inc. uses are: Google Analytics, WordPress, WordPress.

What are Lixte Biotechnology Holdings, Inc.'s office addresses?

Lixte Biotechnology Holdings, Inc. has 2 known office addresses: 433 Plaza Real, Suite 275, Boca Raton, FL 33432 248 Route 25a No. 2, East Setauket, Ny 11733, Us.

What is Lixte Biotechnology Holdings, Inc.'s open headcount?

Lixte Biotechnology Holdings, Inc. has no job postings yet.

What is the number of ad campaigns for Lixte Biotechnology Holdings, Inc.?

Lixte Biotechnology Holdings, Inc. has no advertisements yet.

What is the number of recent news articles about Lixte Biotechnology Holdings, Inc.?

Lixte Biotechnology Holdings, Inc. has 2 news articles.

Lixte Biotechnology Holdings, Inc. - Pubrio Company Profile & Intent

Lixte Biotechnology Holdings, Inc.

United States · Biotechnology

Pharmaceuticals

Biotechnology

Healthcare

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company specializing in the development of new cancer therapies and oncology treatments. Their approach focuses on PP2A inhibition, particularly with their lead compound LB-100, which has shown promise in enhancing both chemotherapy and immunotherapy efficacy in pre-clinical models. They aim to address the challenges of limited efficacy and toxicity associated with traditional cancer treatments.